Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1929 1
1937 1
1940 1
1941 1
1945 3
1946 1
1947 4
1948 4
1950 4
1951 3
1952 4
1953 3
1954 3
1955 3
1956 1
1957 2
1958 2
1959 4
1960 3
1961 4
1962 2
1963 4
1964 11
1965 4
1966 2
1967 3
1968 1
1969 2
1970 8
1971 2
1972 6
1973 1
1974 6
1975 3
1976 3
1977 2
1978 4
1979 4
1980 4
1981 3
1982 2
1983 5
1984 8
1985 5
1986 6
1987 10
1988 8
1989 11
1990 4
1991 7
1992 8
1993 11
1994 17
1995 12
1996 15
1997 26
1998 22
1999 23
2000 21
2001 16
2002 16
2003 13
2004 23
2005 21
2006 34
2007 32
2008 38
2009 34
2010 44
2011 44
2012 33
2013 44
2014 33
2015 32
2016 24
2017 36
2018 28
2019 27
2020 31
2021 18
Text availability
Article attribute
Article type
Publication date

Search Results

891 results
Results by year
Filters applied: . Clear all
Page 1
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Davids MS, et al. Among authors: ross ja. J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095146 Free PMC article.
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Kumar SK, et al. Among authors: ross ja. Lancet Oncol. 2020 Dec;21(12):1630-1642. doi: 10.1016/S1470-2045(20)30525-8. Epub 2020 Oct 29. Lancet Oncol. 2020. PMID: 33129376 Clinical Trial.
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C. Kumar S, et al. Among authors: ross ja. Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10. Blood. 2017. PMID: 29018077 Free article. Clinical Trial.
A Randomized Trial of Progesterone in Women with Recurrent Miscarriages.
Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Bender Atik R, Bloemenkamp KW, Brady R, Briley AL, Cavallaro R, Cheong YC, Chu JJ, Eapen A, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Ross JA, Sharpe L, Stewart J, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. Coomarasamy A, et al. Among authors: ross ja. N Engl J Med. 2015 Nov 26;373(22):2141-8. doi: 10.1056/NEJMoa1504927. N Engl J Med. 2015. PMID: 26605928 Free article. Clinical Trial.
PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation.
Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Atik RB, Bloemenkamp KW, Brady R, Briley A, Cavallaro R, Cheong YC, Chu J, Eapen A, Essex H, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Parrott S, Ross JA, Sharpe L, Stewart J, Trépel D, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. Coomarasamy A, et al. Among authors: ross ja. Health Technol Assess. 2016 May;20(41):1-92. doi: 10.3310/hta20410. Health Technol Assess. 2016. PMID: 27225013 Free PMC article. Clinical Trial.
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J. Place AE, et al. Among authors: ross ja. Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29. Future Oncol. 2018. PMID: 29595064 Free article. Clinical Trial.
Single-dose systemic methotrexate vs expectant management for treatment of tubal ectopic pregnancy: a placebo-controlled randomized trial.
Jurkovic D, Memtsa M, Sawyer E, Donaldson AN, Jamil A, Schramm K, Sana Y, Otify M, Farahani L, Nunes N, Ambler G, Ross JA. Jurkovic D, et al. Among authors: ross ja. Ultrasound Obstet Gynecol. 2017 Feb;49(2):171-176. doi: 10.1002/uog.17329. Epub 2017 Jan 6. Ultrasound Obstet Gynecol. 2017. PMID: 27731538 Free article. Clinical Trial.
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR. de Vos S, et al. Among authors: ross ja. Ann Oncol. 2018 Sep 1;29(9):1932-1938. doi: 10.1093/annonc/mdy256. Ann Oncol. 2018. PMID: 30060083 Free PMC article. Clinical Trial.
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ. Moreau P, et al. Among authors: ross ja. Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28. Blood. 2017. PMID: 28847998 Free article. Clinical Trial.
891 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page